

Sharad Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2130856/publications.pdf>

Version: 2024-02-01

31
papers

593
citations

567281

15
h-index

610901

24
g-index

31
all docs

31
docs citations

31
times ranked

947
citing authors

#	ARTICLE	IF	CITATIONS
1	Ventricular Arrhythmia after Acute Myocardial Infarction: "The Perfect Storm"™. Arrhythmia and Electrophysiology Review, 2017, 6, 134.	2.4	81
2	Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace, 2015, 17, 174-186.	1.7	64
3	Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate. Journal of the American College of Cardiology, 2017, 69, 1669-1678.	2.8	56
4	Premature Ventricular Complex-induced Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2018, 7, 128.	2.4	36
5	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European Heart Journal, 2020, 41, 1976-1986.	2.2	33
6	Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review and meta-analysis. International Journal of Cardiology, 2018, 266, 136-142.	1.7	32
7	Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. European Heart Journal, 2019, 40, 2121-2127.	2.2	29
8	Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2015, 4, .	3.7	28
9	Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator?. Europace, 2018, 20, 897-901.	1.7	28
10	Improved outcome and cost effectiveness in ablation of persistent atrial fibrillation under general anaesthetic. Europace, 2018, 20, 935-942.	1.7	27
11	Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace, 2016, 18, 1187-1193.	1.7	25
12	Cardioverter-defibrillator implantation and generator replacement in the octogenarian. Europace, 2015, 17, 409-416.	1.7	23
13	Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. Heart, 2017, 103, 753-760.	2.9	21
14	Post-acute management of the acquired long QT syndrome. Postgraduate Medical Journal, 2014, 90, 348-358.	1.8	17
15	Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. International Journal of Cardiology, 2018, 262, 51-56.	1.7	17
16	Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis. Europace, 2018, 20, 481-491.	1.7	15
17	Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis. Europace, 2018, 20, 89-96.	1.7	14
18	Ventricular arrhythmia storm in the era of implantable cardioverter-defibrillator. Postgraduate Medical Journal, 2015, 91, 519-526.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Ablation of Complex Fractionated Electrograms Improves Outcome in Persistent Atrial Fibrillation of Over 2 Yearsâ€™ Duration.. Journal of Atrial Fibrillation, 2018, 10, 1607.	0.5	8
20	Acute and sub-acute sinus node dysfunction following pulmonary vein isolation: a case series. European Heart Journal - Case Reports, 2018, 2, ytx020.	0.6	7
21	Implantable cardioverter-defibrillator elective generator replacement: a procedure for all?. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 209-218.	1.3	6
22	Management of ventricular tachycardia storm. Heart, 2021, 107, 1671-1677.	2.9	3
23	CASPA (CArdiac Sarcoidosis in PAPworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study. BMJ Open Respiratory Research, 2020, 7, e000608.	3.0	3
24	Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?. International Journal of Cardiology, 2016, 203, 184-186.	1.7	2
25	Prophylactic implantable cardioverter defibrillator in heart failure: the growing evidence for all or Primum non nocere for some?. Heart Failure Reviews, 2017, 22, 305-316.	3.9	2
26	Letter by Barra et al Regarding Article, â€œREPLACE DARE (Death After Replacement Evaluation) Score: Determinants of All-Cause Mortality After Implantable Device Replacement or Upgrade From the REPLACE Registryâ€• Circulation: Arrhythmia and Electrophysiology, 2015, 8, 513-513.	4.8	1
27	Cardiac resynchronization therapy defibrillator at the end of battery life: In an era of economic uncertainty, do super-responders provide an opportunity for resource optimization?. International Journal of Cardiology, 2015, 199, 384-385.	1.7	1
28	Palpitations in a 72-year-old woman. Heart, 2017, 103, 1554-1555.	2.9	1
29	Dualâ€•site right ventricular pacing in patients undergoing cardiac resynchronization therapy: Results of a multicenter propensityâ€•matched analysis. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1113-1120.	1.2	1
30	Use of Cardiac Resynchronisation Therapy â€œ Change of Clinical Settings. Arrhythmia and Electrophysiology Review, 2014, 3, 20-24.	2.4	1
31	Authors' reply. Europace, 2015, 17, 1456-1456.	1.7	0